Limits...
Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry.

Filippini M, Bazzani C, Atzeni F, Sarzi Puttini P, Marchesoni A, Favalli EG, Caporali R, Cavagna L, Gorla R - Biomed Res Int (2014)

Bottom Line: This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA.Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years.

View Article: PubMed Central - PubMed

Affiliation: Rheumatology and Immunology Unit, Spedali Civili di Brescia, Piazza le Spedali Civili 1, 125123 Brescia, Italy.

ABSTRACT
This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA. Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years.

Show MeSH
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4109221&req=5

Mentions: The change in HAQ scores over time had a biphasic course (Figure 1), with a rapid clinical improvement in the first year (ΔHAQ 0-1: −0.53; P < 0.05), followed by a further slower improvement that did not become clinically or statistically significant until the end of the followup (ΔHAQ 1–5: −0.25; P < 0.05). The functional improvement was even more striking (ΔHAQ 0–5: −0.81; P < 0.05) among the 459 patients in clinical remission (44.43%; DAS28 < 2.6), and there was no disability after the 30th month of followup. Interestingly, there was a temporal dissociation between the time of clinical remission (21st month) and the time of maximum functional improvement (60th month).


Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry.

Filippini M, Bazzani C, Atzeni F, Sarzi Puttini P, Marchesoni A, Favalli EG, Caporali R, Cavagna L, Gorla R - Biomed Res Int (2014)

© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4109221&req=5

Mentions: The change in HAQ scores over time had a biphasic course (Figure 1), with a rapid clinical improvement in the first year (ΔHAQ 0-1: −0.53; P < 0.05), followed by a further slower improvement that did not become clinically or statistically significant until the end of the followup (ΔHAQ 1–5: −0.25; P < 0.05). The functional improvement was even more striking (ΔHAQ 0–5: −0.81; P < 0.05) among the 459 patients in clinical remission (44.43%; DAS28 < 2.6), and there was no disability after the 30th month of followup. Interestingly, there was a temporal dissociation between the time of clinical remission (21st month) and the time of maximum functional improvement (60th month).

Bottom Line: This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA.Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years.

View Article: PubMed Central - PubMed

Affiliation: Rheumatology and Immunology Unit, Spedali Civili di Brescia, Piazza le Spedali Civili 1, 125123 Brescia, Italy.

ABSTRACT
This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA. Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years.

Show MeSH